BEDROCK Act
Sponsored By: Representative Latta, Robert E. [R-OH-5]
Introduced
Summary
Promote U.S. biomanufacturing competitiveness. This bill would create a Department of Commerce program to map federal processes, identify vulnerabilities in critical biomanufacturing supply chains, and coordinate voluntary industry practices with agencies like FDA and EPA.
Show full summary
- Manufacturers and suppliers would get a public web map and designated agency points of contact to find which FDA or EPA processes apply and to access federal commercialization resources. The bill also pushes voluntary, evidence‑based best practices for supplier qualification, product quality, and information sharing.
- Small and medium-sized businesses and innovators would be invited into consultations and public input opportunities and would see prioritized action plans that identify domestic production gaps and options to reduce reliance on foreign adversaries. The program emphasizes participation by non‑Federal U.S. stakeholders.
- Commerce would designate a senior official to lead activities, produce an initial assessment within one year and assessments every two years, and submit reports and a public Commercialization Pathway Map to Congress. A nonpublic annex can protect trade secrets and sensitive supply‑chain details and the requirements would sunset after five years.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Commerce lead for biomanufacturing
If enacted, the bill would require the Commerce Secretary to name a senior biomanufacturing official within 1 year. The Department of Commerce would publish a public Federal Commercialization Pathway Map/report within 1 year and update it when federal processes change. DOC would do a supply‑chain assessment within 1 year and every 2 years after, each with a prioritized action plan listing risks and federal programs that could help. DOC would publish voluntary industry commercialization practices within 1 year, and FDA and EPA must each name a point of contact within 180 days to help businesses find regulatory information. Companies could submit confidential trade secrets and supply‑chain vulnerability information for DOC use, and the program duties would end five years after enactment.
Sponsors & CoSponsors
Sponsor
Latta, Robert E. [R-OH-5]
OH • R
Cosponsors
Rep. Dingell, Debbie [D-MI-6]
MI • D
Sponsored 8/27/2026
Rep. Vindman, Eugene Simon [D-VA-7]
VA • D
Sponsored 9/14/2026
Rep. Gottheimer, Josh [D-NJ-5]
NJ • D
Sponsored 9/14/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov